Mesothelioma Ongoing Clinical Trials - Phase I

Cleveland, OH: Case Comprehensive Cancer Center

Correlate optical coherence tomography images of the airway with airway histology. Develop an imaging technique to detect premalignant airway epithelial changes (carcinoma in situ, dysplasia) to study the transformation process as well as intervene and prevent the development of lung cancer.

Houston, TX: M. D. Anderson Cancer Center at University of Texas

The primary objective of this novel Phase I trial will be the level of biomarker modulation of p-Src Tyr 419 by induction dasatinib therapy in patients with resectable malignant pleural mesothelioma.

Boston, MA: Dana-Farber/Brigham and Women's Cancer Center

This is a Phase I trial to study the efficacy of combination chemotherapy consisting of gemcitabine and cisplatin administered in the operating room and put into the chest and abdomen for one hour. Also being looked at are the effects of heating the chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents: amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy.

Minneapolis, MN: Masonic Cancer Center at University of Minnesota

Sorafenib and Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with pemetrexed and cisplatin may kill more tumor cells.

New York, NY: Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center

The purpose of this study is to determine safety and toxicity for the combination of Temozolomide and Azacitidine in the treatment of Advanced Soft Tissue Sarcoma or Malignant Mesothelioma. This is a single-center, open-label, single-arm Phase I dose-escalation trial. Patients will be evaluated with complete history and physical as well as laboratory studies (complete blood count, metabolic panel, liver function tests), biopsy, and imaging of all sites of measurable disease. This study will be conducted over the course of 3 years.

Baltimore, MD: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Philadelphia, PA: Abramson Cancer Center of the University of Pennsylvania

Dallas, TX: Mary Crowley Medical Research Center at Sammons Cancer Center

This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment. CRS-207 has been altered in the lab to reduce its ability to cause disease, while maintaining stimulation of the immune system. CRS 207 has also been genetically modified with recombinant DNA to release an antigen called Mesothelin. Because CRS 207 stimulates an immune response to Mesothelin and Mesothelin may be present at higher levels on tumor cells than on normal cells, this clinical trial will also examine if CRS 207 boosts the immune system in a way that targets certain types of cancer.

Bethesda, MD: Warren Grant Magnuson Clinical Center

This Phase I trial is studying the side effects and best dose of immunotoxin therapy when given together with pemetrexed and cisplatin in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.

Chicago, IL: Rush Cancer Institute at Rush University Medical Center

Houston, TX: M. D. Anderson Cancer Center at University of Texas

This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural mesothelioma patients.

Denver & Aurora, CO: Pfizer Investigational Site

This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.

Houston, TX: M. D. Anderson Cancer Center at University of Texas

Primary Objectives:
1. To establish acceptable dosages of paclitaxel, oxaliplatin and bevacizumab
2. To assess toxicity profile.
3. To assess clinical responses.

Philadelphia, PA: Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) which seems to be an approach to tumor cure.

Houston, TX: M. D. Anderson Cancer Center at University of Texas

Primary Objective:
1. To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma.

New York, NY: Memorial Sloan-Kettering Cancer Center

Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from growing.

Indianapolis, IN: Indiana University Melvin and Bren Simon Cancer Center;

Houston, TX: M. D. Anderson Cancer Center at University of Texas

The purpose of this research study is to determine the highest dose of the drug (BMS-690514) that can be safely given to patients with advanced cancer.

Philadelphia, PA: Abramson Cancer Center of the University of Pennsylvania

This Phase I study will evaluate the safety of two doses of BG00001. Eligible subjects will have malignant pleural mesothelioma or pleural effusions who have progressed through at least one prior therapy or have refused therapy.

Bethesda, MD: NCI - Center for Cancer Research & Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office

Drugs used in chemotherapy, such as FR901228 and flavopiridol, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving FR901228 together with flavopiridol may kill more tumor cells.

Bethesda, MD: NCI - Center for Cancer Research & Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office

This phase I trial is studying the side effects and best dose of decitabine and FR901228 in treating patients with unresectable advanced lung cancer, esophageal cancer, pleural mesothelioma, or lung metastases.